The strategy for the present clinical trial was as follows: (1) Determine the HLA haplotype identity in the active exudate of AMD patients, (2) use HLA homozygote iPS-RPE cells from the iPS bank at CiRA, and (3) perform simultaneous one-shot anti-VEGF and local steroid therapies during the surgical procedure. The gene discussed is VEGFA; the disease is age-related macular degeneration.